Major Depressive Disorder Clinical Trial
Official title:
Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)
Late-life depression is characterized by both affective (mood) symptoms and cognitive
deficits. There is currently no intervention that may provide consistent benefits to both
mood and cognitive performance. Agonist activity at the nicotinic acetylcholine receptors via
transdermal nicotine patches may provide benefit to both mood and cognition, working through
nicotine's effects on brain neural networks, specifically the cognitive control network and
default mode network.
In this initial pilot project, the investigators will test this hypotheses in 15 nonsmoking
depressed elders with subjective cognitive impairment. Following baseline neuroimaging and
cognitive testing, participants will receive 12 weeks of open-label transdermal nicotine.
Afterwards, participants will repeat neuroimaging and cognitive assessments.
Late-life depression (LLD) is characterized both by affective symptoms and cognitive
deficits. The co-occurrence of cognitive deficits in LLD is a clinically relevant phenotype
characterized by significant disability and poor antidepressant response. Cognitive deficits
can persist even with successful antidepressant treatment and increase the risk of depression
relapse. Despite the clinical importance of cognitive deficits in LLD, there are no
established treatments that specifically target cognition in this population. The lack of
treatments that improve cognitive deficits in depression is a deficiency in current
therapeutics.
Modulation of the cholinergic system by nicotinic receptor stimulation may improve both mood
and cognition in depressed elders. Clinically, transdermal nicotine improves mood in smokers
and a placebo-controlled pilot trial in nonsmoking adults found that transdermal nicotine
significantly improved mood. In a previous trial examining Mild Cognitive Impairment,
transdermal nicotine safely improved cognitive function on tests of attention, episodic
memory, and processing speed. These same cognitive domains are impaired in LLD. The
investigators hypothesize that these effects on mood and cognition are mediated through
nicotine's effect to increase cognitive control network activity and reduce default mode
network (DMN) activity. This pattern of network activity during tasks demanding external
attention is associated with better task performance. Furthermore, as seen in smokers,
nicotine's effect on these networks reduces depression's bias to negatively valenced stimuli
and decreases rumination.
The central hypothesis is that in LLD, transdermal nicotine will safely improve depression by
increasing activity in cognitive control regions and decreasing activity in DMN regions. This
will result in a decreased attentional bias to and reactivity to negative stimuli. A
secondary hypothesis is that transdermal nicotine will also improve subjective and objective
cognitive performance through these same network effects.
Primary Aim 1: To determine whether administration of transdermal nicotine over 12 weeks
improves clinical symptoms in patients with LLD with subjective cognitive impairment (SCI).
Hypothesis 1: Transdermal nicotine administration will result in reductions in depression
severity measured by the Montgomery-Asberg Depression Rating Scale (MADRS; primary mood
outcome). It will also result in improvement in broader assessments of depressive
symptomatology, including anhedonia, apathy, fatigue, sleep, and rumination (secondary
outcomes).
Hypothesis 2: Transdermal nicotine administration will result in improvements in attentional
performance on the Conner's Continuous Performance Task (CPT; primary cognitive outcome). It
will also result in improvement in subjective and objective cognitive performance on other
tasks measuring attention, episodic memory, working memory, processing speed, and executive
function (secondary outcomes).
Secondary Aim 2: To determine whether administration of transdermal nicotine over 12 weeks
modulates canonical intrinsic functional network activity in LLD with SCI.
Hypothesis 3: On repeat administration of the Posner task of external attention, transdermal
nicotine administration will result in increased activity within the cognitive control
network and decreased activity within the default mode network.
Hypothesis 4: Transdermal nicotine administration will result in increased functional
connectivity within the cognitive control network and decreased connectivity within the
default mode network at rest.
Hypothesis 5: Changes in intrinsic network activity / connectivity with transdermal nicotine
administration will be associated with changes in mood symptoms and subjective and objective
cognitive performance.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |